

### REMARKS

By this amendment, Applicants have added new claims 35-79. The subject matter of these claims is supported by the specification, for example, page 5, last paragraph; page 27, fourth paragraph to page 28, third paragraph; page 29, third paragraph to page 30, second paragraph; page 38, third paragraph; and the examples, especially example 3, 5, and 6. In particular, the vector referred to in claim 38 is described on page 15, third paragraph, the DNA, RNA, and antisense sequences referred to in claims 39-41 are described on page 13, fourth paragraph, the complementary counter-strand referred to in claim 42 is described on page 27, last line, the modification and labeling referred to in claims 43 and 44 are disclosed on page 14, last paragraph and page 28, first paragraph. The detectible marker referred to in claims 45 and 46 is disclosed on page 36, last paragraph and page 38, third paragraph, the carrier material referred to in claim 47 is disclosed on page 36, first paragraph and page 38, fourth paragraph to page 39, first paragraph, the PCR reaction referred to in claim 48 is disclosed on page 27, fifth paragraph, and the different diseases referred to in claims 49, 78, and 79 are disclosed in claims 33 and 34 as originally filed.


No new matter has been added by the amendments.

If there are any charges or any credits, please apply them to Deposit Account No.

03-2095.

Respectfully submitted,

Date: 20 February 2003

  
\_\_\_\_\_  
Karen L. Elbing, Ph.D.  
Reg. No. 35,238

Clark & Elbing LLP  
101 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045

FA50125\50125.015002 PRELIMINARY AMENDMENT.doc

